BNP Paribas Purchases 7,624 Shares of CVS Health Corporation $CVS

BNP Paribas grew its holdings in CVS Health Corporation (NYSE:CVS) by 293.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,224 shares of the pharmacy operator’s stock after acquiring an additional 7,624 shares during the quarter. BNP Paribas’ holdings in CVS Health were worth $811,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of CVS. Vanguard Group Inc. grew its holdings in shares of CVS Health by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after purchasing an additional 1,824,424 shares in the last quarter. Capital World Investors lifted its position in CVS Health by 2.1% during the third quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock worth $5,155,380,000 after purchasing an additional 1,419,575 shares during the period. State Street Corp grew its stake in CVS Health by 0.3% during the third quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator’s stock worth $4,443,357,000 after buying an additional 149,701 shares in the last quarter. Capital International Investors increased its holdings in CVS Health by 1.1% in the 3rd quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator’s stock valued at $2,012,347,000 after buying an additional 302,499 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of CVS Health by 3.2% during the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock worth $1,831,454,000 after acquiring an additional 760,579 shares during the period. 80.66% of the stock is owned by institutional investors.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Truist raised its price target on CVS Health to $108 from $102 and kept a Buy rating, signaling continued upside potential for the shares. Article Title
• Positive Sentiment: CVS was highlighted by Zacks as a strong value stock and a name attracting investor attention, which can reinforce bullish sentiment around the shares. Article Title
• Positive Sentiment: CVS Health is leveraging AI in pharmacy dispensing, suggesting efficiency gains and a push to improve operations over time. Article Title
• Neutral Sentiment: CVS published a company update about helping seniors navigate digital-first health care, which is positive for its brand but not likely to move the stock on its own. Article Title
• Neutral Sentiment: Market commentary noted CVS is attracting investor attention and compared its dividend profile with UnitedHealth, but this was largely discussion-oriented rather than a new catalyst. Article Title
• Negative Sentiment: CVS faces a lawsuit alleging it pocketed $250 million in drug savings meant for uninsured patients, adding legal and reputational overhang. Article Title
• Negative Sentiment: Eli Lilly said it won back CVS Health’s support on GLP-1 access, reversing Novo Nordisk’s advantage; the headline is more about Lilly, but it suggests CVS is still central to intense pricing and access battles in weight-loss drugs. Article Title

Insider Activity at CVS Health

In other CVS Health news, Director Larry Robbins sold 370,462 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the sale, the director owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,441,551 shares of company stock worth $323,703,977 over the last quarter. 0.85% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on CVS. UBS Group boosted their price objective on shares of CVS Health from $97.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft boosted their price target on CVS Health from $88.00 to $92.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. JPMorgan Chase & Co. upped their price objective on CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Argus lifted their target price on CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. Finally, Barclays boosted their target price on CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 26th. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and an average target price of $99.68.

CVS Health Stock Performance

NYSE:CVS opened at $89.70 on Wednesday. The stock’s 50-day moving average is $82.44 and its 200-day moving average is $79.64. The stock has a market cap of $114.45 billion, a P/E ratio of 39.51, a price-to-earnings-growth ratio of 0.89 and a beta of 0.62. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $98.43. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same period in the previous year, the firm posted $2.25 EPS. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts anticipate that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health’s payout ratio is currently 117.18%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.